ロード中...
HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy
The ideal endpoint of hepatitis B virus (HBV) antiviral therapy is HBsAg loss, a difficult goal to obtain, especially in HBeAg negative patients. Herein, we report the results obtained by the addition of peg-interferon α-2a to a long-lasting nucleos(t)ide analogue therapy in a HBeAg negative, genoty...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Baishideng Publishing Group Inc
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4093726/ https://ncbi.nlm.nih.gov/pubmed/25024631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i26.8722 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|